The Molekule team will challenge the audience to think differently about the purpose and role of the CI function and explain from experience how to create an influential, integrated function that is respected and integral to decision making. It has a lot to do with purpose and position. For those who already lead in-house teams this presentation will challenge your role and goals and make you think differently about how your function is positioned.

• Understand the interlink between RWE and CI – RWE to inform strategies and CI to drive RWE approaches
• Benchmark competitors’ RWE strategies
• Develop RWE-driven go-to-market, market access and life cycle management strategies

• Captive versus outsourced development and manufacturing models
• CI’s role and contribution to S&OP and commercialization
• Integrating manufacturing intel into current CI programs

• 3rd party integration
• Housing and indexing internal files
• Walkthrough of ProactivePulse

We need new tools now to help us sort, distill, categorize, and prioritize the events around us to deliver the insights that our business partners depend on. Most of our success in this effort has been through integrating in various combinations our own proprietary libraries with the powerful NLP, NER, and neural network tools. Please join us as we review our learnings and applications of these to real life business case studies.

Using the power of the latest technology, SPRING consolidates all your intelligence around a topic, disease area, mechanism of action, competitor, in a structured manner. Your internal teams can have access to allow fast & easy searching to connect all the dots across your clinical & commercial intelligence, across your organization.

SPRING uses transcription technology to make sure all your insights are integrated into your dedicated platform. Let’s take a look at how AI can benefit you in your CI workflow and most importantly, tremendously increase your CI efficiency.

While there are automated tools to collect and source news feeds- analysis, curation and distribution of competitive insights still remains a huge challenge. This session’s goal is to share how digital technologies can help in creating a single, unified productivity and workflow platform to collect, curate, and deliver intel/alerts to enable better and faster decision-making across the organization.

1. Understanding of Integrated CI methodology across healthcare ecosystem which provides 360-degree insights
2. Development of stronger CI and BI insights roadmap and intuitive visualization for CI end users
3. Empower CI end users with real-time data reporting and analytics topped with social media and web insights

What does this mean for pharmaceutical companies applying for marketing authorisation in the EU and the UK?

Dig Worldwide will guide attendees through a map of this altered territory for medicine approvals in the EU and the UK, with key dates along assessment timelines. You will learn the procedural options available, how fast your clients’ competitors could reach market depending on the pathway to approval they choose, and what all this could mean for UK Pharma.

How do their systems and practices relate specifically to the competitive intelligence function at leading pharma companies? In this webinar we’ll draw on IDC’s recent research findings on “intelligent knowledge networks” to offer insights into:

What capabilities and best practices make an organization a “transformer” in the competitive intelligence space; and
How being an advanced KM user benefits business decision-making and decision-makers in the pharma industry

• Focus groups and conferences, what, how, where, when and who.
• Transforming how an organization makes decisions (case study)

• Practical thoughts will be discussed on the key factors to consider when designing and implementing innovative tool-based data analytics solutions focusing upon discrete competitive landscapes

This data is spread across a variety of disparate sources making comparisons and actionable insights cumbersome. With the CLIN cancer trial results platform, our team is combining text mining and curation to put all the data into a common, searchable model. To further enhance insights through this platform, we are also digitizing outcomes data to enable quick meta-analyses and using social listening to give users a view of how digital opinion leaders are reacting to new data releases.

That all changed when the COVID-19 pandemic forced many medical offices to restrict visitors and pharmaceutical sales reps. A lasting impact has been a re-focusing of the sales rep role and a restructuring of the sales structure.

This session will explore how pharmaceutical sales evolved in the COVID-19 era and how that evolution will continue in the post-COVID era. The impacts include changes in how salespeople interact with the medical community, the role of technology in the sales program, and how sales will integrate with other commercial and medical support resources.

It is very likely that there will be continued changes in the sales force over the next few years as the early adaptions to COVID restrictions are refined and made permanent. In this session, some of the change drivers and how they will be implemented will be debated. If you are concerned about where your field force, or your competitors’, is going, it is a can’t miss session.

No longer can competitor, market and stakeholder intelligence be delivered on an ad hoc basis in a format that is difficult to decipher; decision-makers require dynamic, targeted, high-impact insight that provides clarity and empowers them to act in a timely manner.

The clinical and commercial aspects of traditional competitive intelligence are enhanced with the addition of HEOR messaging, field-based reimbursement teams, directional contracting and marketing strategies. This session will review FADAMA 114 and the PIE Act and provide examples of market access intelligence including, rebating/contracting, value-based agreements, adherence-based contracts, pay for performance contracts and various hybrid reimbursement models. Please join us for an informative presentation to help you see the full picture to inform your strategy.

• Captive versus outsourced development and manufacturing models
• CI’s role and contribution to S&OP and commercialization
• Integrating manufacturing intel into current CI programs

• Advance your understanding of core regulatory routes, timelines and strategies
• Understand core Gx/biosimilar product development and entry strategies
• Learn from & set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
The presentation will be supported by thought provoking real-world case studies to stress differences between theory vs actual approaches

Developing, launching and growing blockbuster brands require a well defined strategic decision making process.

In this presentation, we will share our proven 3 step process needed to identify your key competitors, assess several credible scenarios, and identify the key success factors, risks and concrete actions to execute your winning strategy.

The presentation incorporates learnings from leading the CI functions at Roche and Novartis, supporting the majority of Big Pharma companies CI efforts, and the latest management thinking from Harvard Business School.

We look forward to seeing you there!